Personalized approach to muscle regeneration holds promise for longevity

Partner content

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

MUVON cofounder explains how muscle regenerating technology has the potential to boost healthspan and help treat a major women’s health condition.

Swiss biotech MUVON Therapeutics today announced positive interim data from the Phase 2 clinical trial of its skeletal muscle tissue regeneration therapy. The ongoing SUISSE MPC2 study is assessing the safety and efficacy of MUVON’s muscle precursor cell (MPC)-based therapy for the treatment of stress urinary incontinence in women.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Danny Sullivan

Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Beauty giant and supplement startup both chase skin aging

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE